Bayer's Pipeline Push Meets Its Courtroom Clock

Bayer's Kerendia becomes the first new type 1 diabetes kidney disease therapy in the US in 30 years, as the company raises EUR 2 billion in hybrid bonds.

A double dose of good news landed on Bayer this month, and investors responded in kind. On 17 September, the US Food and Drug Administration cleared Kerendia — known generically as finerenone — for treating chronic kidney disease in patients with type 1 diabetes. It is the first new therapy option in that American market segment in three decades, and management believes the drug could eventually generate peak annual sales north of EUR 3 billion.

That regulatory win arrived alongside fresh capital. Bayer placed two hybrid bonds totaling EUR 2 billion on Wednesday, split into EUR 1 billion tranches with 30-year maturities and coupons of 5.75% and 6.25%. Demand ran hot: both tranches were multiple times oversubscribed, according to the company, and proceeds are earmarked for general corporate purposes. The issue lifts Bayer's outstanding hybrid debt to EUR 6.55 billion.

The financing push is part of a broader pattern. In mid-September, Apollo Funds and KKR closed a EUR 3 billion capital solution for Bayer's long-acting reversible contraceptive business, a deal that leaves the German group with operational control and a majority stake in the newly formed entity. Bayer is also trimming its portfolio on the other side of the ledger, selling the cancer drug Stivarga to Grünenthal in a transaction worth up to EUR 375 million. That deal is expected to close in late 2026 or early 2027.

A Pipeline With Momentum

The Kerendia approval matters because it opens a market where unmet need has gone unaddressed for more than 30 years. If uptake accelerates, it would strengthen visibility for Bayer's pharmaceutical division for years and give the company room to fund its own research without expensive acquisitions. The FDA also granted accelerated approval to Sevabertinib earlier in September for first-line treatment of adults with HER2-mutated non-small cell lung cancer. In Crop Science, Bayer is preparing to roll out additional products including Vyconic and Intacta 5+ as it modernizes its agricultural portfolio.

Ownership signals point the same direction. French asset manager Amundi crossed the 3% reporting threshold on 14 September and now holds 3.04% of voting rights. The stock has climbed 34% since the start of the year, closing at EUR 49.50 in the latest session and entering trading at EUR 49.48.

The Legal Overhang

None of this erases the litigation cloud. A Missouri court held a hearing roughly two weeks ago on final approval of the proposed Roundup settlement, which calls for payments of up to USD 7.25 billion. Bayer's Monsanto subsidiary is awaiting the court's sign-off. The stock has added 1.6% since that hearing, but the complex continues to tie up liquidity and management attention. Until the settlements are fully and legally concluded, the risk of unpredictable additional claims remains a persistent valuation discount.

Execution risk cuts both ways on the pharmaceutical side, too. Regulatory approvals are no guarantee of commercial success. Hitting that EUR 3 billion peak sales target depends on how smoothly Bayer negotiates with payers and how readily specialists write prescriptions. If growth lags forecasts, disappointment in the pharma sector could return quickly.

What the Autumn Hinges On

The path forward depends on how solidly the recent recovery is underpinned. As long as the shares hold above recent interim lows and Kerendia's launch shows measurable progress, the trend stays positive. Legal delays or operational disappointments, however, could bring nervousness back in a hurry.